Close



Apr 8, 2024 08:01AM
Apr 8, 2024 08:00AM
Apr 6, 2024 03:30PM
Mar 25, 2024 08:00AM
Mar 25, 2024 08:00AM
Feb 29, 2024 07:00AM
Jan 10, 2024 07:02AM Amarin Corp. (AMRN) Provides Preliminary Fourth Quarter 2023 Selected Financials and Outlines Key Priorities For 2024
Jan 10, 2024 07:00AM
Dec 4, 2023 08:04AM
Dec 4, 2023 08:03AM
Nov 13, 2023 05:33AM
Nov 12, 2023 09:00AM
Oct 26, 2023 08:00AM
Aug 9, 2023 06:30AM BiomX Reports Second Quarter 2023 Financial Results and Provides Business Update
Jul 31, 2023 08:00AM
Jul 26, 2023 08:01AM
Jul 26, 2023 08:00AM
Jun 21, 2023 09:01AM
Jun 1, 2023 06:00AM
Jun 1, 2023 06:00AM
May 12, 2023 11:00AM Amarin Highlights New Data Providing Potential Mechanistic Insight into Vascepa®/Vazkepa® (Icosapent Ethyl) Reduction of Cardiovascular Events
May 3, 2023 07:00AM
Mar 16, 2023 08:02AM
Mar 16, 2023 08:00AM
Mar 16, 2023 08:00AM
Mar 6, 2023 08:09AM
Mar 6, 2023 08:00AM
Mar 6, 2023 08:00AM Amarin Highlights New Evidence of Therapeutic Value of EPA in Reducing Cardiovascular Events in At-Risk Patients Presented at ACC.23/WCC
Mar 5, 2023 10:21AM
Mar 5, 2023 10:21AM
Mar 1, 2023 07:00AM
Mar 1, 2023 07:00AM
Feb 27, 2023 08:01AM
Feb 27, 2023 08:00AM
Feb 27, 2023 08:00AM Amarin Corporation to Present New Data Evaluating VASCEPA®/VAZKEPA® (Icosapent Ethyl) at ACC.23/WCC
Jan 10, 2023 07:17AM
Jan 10, 2023 07:15AM
Jan 10, 2023 07:15AM
Nov 7, 2022 08:00AM
Nov 7, 2022 08:00AM
Oct 27, 2022 07:00AM
Oct 27, 2022 07:00AM Amarin Reports Third Quarter 2022 Financial Results and Provides Business Update
Aug 28, 2022 05:51AM
Aug 28, 2022 05:51AM
Aug 26, 2022 08:19AM
Aug 26, 2022 08:19AM
Aug 15, 2022 08:01AM
Aug 15, 2022 08:00AM
Aug 15, 2022 08:00AM Latest Research Evaluating VASCEPA®/VAZKEPA (icosapent ethyl) and Subgroups from the REDUCE-IT® Landmark Outcomes Trial to be Presented at the European Society of Cardiology (ESC) Congress
Aug 3, 2022 07:00AM

251,536 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All